Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis (Dermatology and Therapy, (2024), 14, 1, (169-182), 10.1007/s13555-023-01058-z)

Abstract

Authors would like to correct the Error in Fig. 1, which should illustrate that the study arms were compared in the study. As reflected in the text, these are the Q2W arm from the SOLO-CONTINUE study and the Q4W arms from the ADvocate trial. However, the gold border for the ADvocate trials is erroneously placed around the Q2W arms. The revised version of Fig. 1 is updated here. The revised version of Table 1 isupdated here. (Table presented.) SOLO-CONTINUE and corresponding ADvocate aggregate data Variable SOLO-CONTINUE Dupilumab QW/Q2W ADvocates 1 & 2 N (%) 169 (100%) 101 (100%) Race Asian, n(%) 31 (18.3%) 14 (13.9%) Other, n(%) 14 (8.3%) 12 (11.9%) Baseline scores (maintenance baseline, week 16 of treatment) EASI-75, n (%) 162 (95.9%) 101 (100%) IGA, mean (SD) 1.15 (0.61) 1.2 (0.85) IGA 0/1, n (%) 129 (76.3%) 63 (62.4%) DLQI, mean (SD) 3.4 (4.21) 3.5 (3.47) POEM, mean (SD) 6.4 (5.3) 7.7 (5.3) End-of-study scores (week 52 of treatment) IGA 0/1, n (%) 68 (40.2%) 56 (55.4%) EASI-75, n (%) 116 (68.6%) 69 (68.3%) Overall AE, n (%) 118 (69.8%) 74 (73.3%) Bold italics for variables used in propensity score weighting SD: Standard Deviation; QW/Q2W: weekly or bi-weekly administration; EASI: Eczema Area and Severity Index; IGA: Investigator Global Assessment; DLQI: Dermatology Life Quality Index; POEM: Patient Oriented Eczema Measure; BSA: Body Surface Area; IGA 0/1: IGA score of 0 or 1, clear/almost clear skin; EASI-75: 75% improvement in EASI score from baseline; AE: Adverse Events Affiliation of authors Kim Rand and Juan Manuel Ramos-Gon updated from ‘Health B.V’ to ‘Maths in Health B.V’. (Figure presented.) ADvocate and SOLO-CONTINUE trial designs. The arms used in this study are outlined in gold The original article has been corrected.